← Eichor
Condition: Skin Toxicity Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Skin Toxicity

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac
Phase 3 · 590 location(s) · SWOG Cancer Research Network · NCT03418961Evaluating an AI-Based Mobile Application for Chemotherapy Support in Breast Cancer Patients
NA · 1 location(s) · Dena h. Al-Tameemi · NCT07273812Predictive Toxicity Test Linked to Radiotherapy After Mastectomy and Immediate Implant Reconstruction
NA · 9 location(s) · Institut du Cancer de Montpellier - Val d'Aurelle · NCT04342546Retrospective Observational Study of the Safety and Toxicity Management of Abemaciclib in Combination with Adjuvant Horm
Phase N/A · 1 location(s) · University Hospital, Brest · NCT06621459Photobiomodulation Therapy in the Management of Hand-foot Syndrome and Hand-foot Skin Reaction
NA · 2 location(s) · Jessa Hospital · NCT04979078Impact of Genetic Variants on the Toxicity of Antibody-Drug Conjugates in Locally Advanced or Metastatic Breast Cancer:
Phase N/A · 1 location(s) · Fundación Pública Andaluza para la Investigación Biomédica A · NCT07582887Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity Management
Phase 2 · 27 location(s) · SOLTI Breast Cancer Research Group · NCT07371585Chronic Toxicities Related to Treatment in Patients With Localized Cancer
NA · 1 location(s) · UNICANCER · NCT01993498Sacubitril/Valsartan in PriMAry preventIoN of the Cardiotoxicity of Systematic breaST canceR trEAtMent (MAINSTREAM)
Phase 4 · 4 location(s) · Silesian Centre for Heart Diseases · NCT05465031Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted
Phase 2 · 10 location(s) · Rutgers, The State University of New Jersey · NCT05559164Evaluation of Skin Health and QoL in Pts Receiving Anti-PD1/PDL1/CTLA4 or CDK Inhibitors.
Phase N/A · 1 location(s) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · NCT05878964Ultra Hypo-fractionated Adjuvant Whole Breast Radiation Therapy With Simultaneous Integrated Boost for Early-Stage Breas
Phase 2 · 1 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT06902311Next-gen Flow Cytometry to Find Immune Profiles, Treatment Response, and Toxicity Markers in Skin Cancer Patients Treate
Phase N/A · 1 location(s) · Instituto de Investigación Biomédica de Salamanca · NCT07064330OligoCare TwiCs (Trials Within Cohorts) Trial Comparing Acute Toxicity in Single-fraction vs Multiple-fraction SBRT for
NA · 15 location(s) · European Organisation for Research and Treatment of Cancer - · NCT06462963Toxicity Markers to Trastuzumab-Deruxtecan (T-DXd) In Patients With Advanced Breast Cancer
Phase N/A · 1 location(s) · European Institute of Oncology · NCT07049133Effect of Genetic Polymorphism on Capecitabine-Induced Toxicity in Egyptian Cancer Patients
Phase N/A · 1 location(s) · Ain Shams University · NCT06765252Preoperative Partial Breast Irradiation in Early-Stage Breast Cancer
Phase 2 · 1 location(s) · Yonsei University · NCT06677944IMmune checkPoint Inhibitor Related gonAdal toxiCiTy in Premenopausal Women and Men With Melanoma
Phase N/A · 6 location(s) · Peter MacCallum Cancer Centre, Australia · NCT07138222Real-world Study on the Management of Hematological Toxicities Associated With Targeted Therapies for Breast Cancer
Phase N/A · 1 location(s) · Fudan University · NCT06503380Efficacy and Safety of Ultra_HYPofractionated RadiotHerapy in Women With BrEast CaNcer Receiving Regional Nodal Radiatio
NA · 1 location(s) · Instituto Brasileiro de Controle do Cancer · NCT05665920Acute and Long-term Cardiovascular Toxicity After Modern Radiotherapy for Breast Cancer
Phase N/A · 2 location(s) · St. Olavs Hospital · NCT02541435Evaluation of the Efficacy and Safety of Methylprednisolone Combined With the JAK Inhibitors in the Treatment of Toxic E
EARLY_Phase 1 · 1 location(s) · Peng Zhang · NCT06119490A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
Phase 1 · 6 location(s) · Edgewood Oncology Inc. · NCT04872166The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
Phase N/A · 18 location(s) · UMC Utrecht · NCT04075305Safety and Efficacy of IMPT or IMRT for Breast Cancer
Phase N/A · 1 location(s) · Ruijin Hospital · NCT06826885Real-world Data in Patients With Breast Cancer Treated With Abemaciclib
Phase N/A · 1 location(s) · Hellenic Cooperative Oncology Group · NCT04985058Aspects of Adjuvant CDK4/6 Inhibitors in Older Breast Cancer Patients - Focusing on Geriatric Screening
Phase N/A · 5 location(s) · Region Jönköping County · NCT07273357A Study of Treatment-Related Toxicities and Quality of Life After Local Therapy in Chinese Breast Cancer Patients
Phase N/A · 3 location(s) · FangYi · NCT07010939Investigating Paclitaxel Toxicity in Breast Cancer: the Roles of Physical Activity and Body Composition.
Phase N/A · 2 location(s) · Universitair Ziekenhuis Brussel · NCT06387901Oncologic Outcomes and Toxicities of Salvage Treatment in Patients With Locoregionally Recurrent Breast Cancer
Phase N/A · 1 location(s) · Samsung Medical Center · NCT05933733
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.